Quality of direct oral anticoagulant prescribing in elderly patients with non-valvular atrial fibrillation: results from a large urban health system

  • Shakira J. Grant
  • Shawn Kothari
  • Phyllis A. Gimotty
  • Nalaka S. Gooneratne
  • Adam Cuker
Article

Abstract

Non-valvular atrial fibrillation (NVAF) is common in older adults. Oral anticoagulation is indicated to reduce the risk of stroke and systemic embolism, but it also poses a risk of bleeding, particularly in the elderly. Direct oral anticoagulants (DOACs) provide an alternative to warfarin and their use in the treatment of AF is growing. We conducted a retrospective cohort study to assess the quality of DOAC prescribing in elderly patients with NVAF in a large academic health system and to compare practice with consensus best practice recommendations. We searched the electronic medical record for patients ≥ 65 years of age who were newly initiated on a DOAC for AF from January 2013 through December 2015. Patient and provider characteristics, baseline laboratory investigations, concomitant medications, and interval to first follow-up were recorded. 192 patients met eligibility criteria. The most commonly prescribed DOACs were rivaroxaban (65%) and apixaban (26%). Despite consensus recommendations that patients have a baseline creatinine, complete blood cell count, and coagulation studies prior to DOAC initiation, these tests were not performed in 18, 31, and 67% of patients, respectively. Consensus recommendations also suggest a follow-up visit within 1 month of DOAC initiation. However, only 39% of patients had a return visit within 6 weeks and 43% did not have follow-up within 12 weeks. DOAC prescribing in elderly patients with NVAF frequently fell short of quality standards. Interventions to enhance the quality of DOAC prescribing in this high-risk population are needed.

Keywords

Apixaban Atrial fibrillation Dabigatran Direct oral anticoagulants Elderly Rivaroxaban 

Notes

Compliance with ethical standards

Conflict of interest

AC has received research support from Alexion, Bayer, Bioverativ, Novo-Nordisk, Pfizer, Shire, Spark Therapeutics, and Syntimmune and served as a consultant for Genzyme, Kedrion, and Synergy. The other authors have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

References

  1. 1.
    Connolly SJ, Ezekowitz MD, Yusuf S et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:1139–1151CrossRefPubMedGoogle Scholar
  2. 2.
    Granger CB, Alexander JH, McMurray JJV et al (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365:981–992CrossRefPubMedGoogle Scholar
  3. 3.
    Patel MR, Mahaffey KW, Garg J et al (2011) Rivaroxaban versus warfarin in non-valvular atrial fibrillation. N Engl J Med 365:883–891CrossRefPubMedGoogle Scholar
  4. 4.
    Giugliano RP, Ruff CT, Braunwald E et al (2013) Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 369:2093–2104CrossRefPubMedGoogle Scholar
  5. 5.
    Kirley K, Qato DM, Kornfield R, Stafford RS, Alexander GC (2012) National trends in oral anticoagulant use in the United States, 2007 to 2011. Circ Cardiovasc Qual Outcomes 5:615–621CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Pattullo CS, Barras M, Tai B, McKean M, Donovan P (2016) New oral anticoagulants (NOACs)—appropriateness of prescribing in real-world setting. Intern Med J 46:812–818CrossRefPubMedGoogle Scholar
  7. 7.
    Barra ME, Fanikos J, Connors JM, Sylvester KW, Piazza G, Goldhaber SZ (2016) Evaluation of dose-reduced direct oral anticoagulant therapy. Am J Med 129:1198–1204CrossRefPubMedGoogle Scholar
  8. 8.
    Stöllberger C, Finsterer J (2013) Concerns about the use of new oral anticoagulants for stroke prevention in elderly patients with atrial fibrillation. Drugs Aging 30:949–958CrossRefPubMedGoogle Scholar
  9. 9.
    Stöllberger C, Brooks R, Finsterer J, Pachofszky T (2016) Use of direct-acting oral anticoagulants in nonagenarians: a call for more data. Drugs Aging 33:315–320CrossRefPubMedGoogle Scholar
  10. 10.
    Sardar P, Partha S, Saurav C, Shobhana C, Lip GYH (2014) New oral anticoagulants in elderly adults: evidence from a meta-analysis of randomized trials. J Am Geriatr Soc 62:857–864CrossRefPubMedGoogle Scholar
  11. 11.
  12. 12.
  13. 13.
  14. 14.
  15. 15.
    Heidbuchel H, Verhamme P, Alings M et al (2015) Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 17:1467–1507CrossRefPubMedGoogle Scholar
  16. 16.
    Kovacs RJ, Flaker GC, Saxonhouse SJ et al (2015) Practical management of anticoagulation in patients with atrial fibrillation. J Am Coll Cardiol 65:1340–1360CrossRefPubMedGoogle Scholar
  17. 17.
    Tran H, Joseph J, Young L et al (2014) New oral anticoagulants: a practical guide on prescription, laboratory testing and peri-procedural/bleeding management. Intern Med J 44:525–536CrossRefPubMedGoogle Scholar
  18. 18.
    Asencio LA, Huang JJ, Alpert JS (2014) Combining antiplatelet and antithrombotic therapy (triple therapy): what are the risks and benefits? Am J Med 127:579–585CrossRefPubMedGoogle Scholar
  19. 19.
    Dans AL, Connolly SJ, Wallentin L, Yang S, Nakamya J, Brueckmann M, Ezekowitz M, Oldgren J, Eikelboom JW, Reilly PA, Yusuf S (2013) Concomitant use of antiplatelet therapy with dabigatran or warfarin in the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial. Circulation 127:634–640CrossRefPubMedGoogle Scholar
  20. 20.
    Shehab N, Lovegrove MC, Geller AI, Rose KO, Weidle NJ, Budnitz DS (2016) US emergency department visits for outpatient adverse drug events, 2013–2014. JAMA 316:2115–2125CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Division of Hematology-Oncology University of WashingtonFred Hutchinson Cancer Research CenterSeattleUSA
  2. 2.Department of MedicineUniversity of ChicagoChicagoUSA
  3. 3.Department of Biostatistics, Epidemiology and InformaticsPerelman School of Medicine, University of PennsylvaniaPhiladelphiaUSA
  4. 4.Department of MedicinePerelman School of Medicine, University of PennsylvaniaPhiladelphiaUSA
  5. 5.Department of Pathology and Laboratory MedicinePerelman School of Medicine, University of PennsylvaniaPhiladelphiaUSA
  6. 6.Penn Comprehensive Hemophilia and Thrombosis ProgramHospital of the University of PennsylvaniaPhiladelphiaUSA

Personalised recommendations